Loading organizations...
§ Venture Capital · Menlo Park, CA, USA
Longitude Capital is a venture capital firm that invests in biotechnology and medical technology companies.
Longitude Capital is a healthcare venture capital firm specializing in venture growth investments across biotechnology, medical technology, and health solutions. It deploys capital into both private and public entities, building balanced portfolios of clinical and commercial stage assets. The firm’s approach targets improved clinical outcomes, enhanced patient quality of life, and reduced healthcare costs through diverse investment structures.
Established in 2006, Longitude Capital was founded by a team investing in life sciences since 2002. The firm's name draws from the historical Longitude Prize, a 1714 British challenge to solve a critical scientific problem. This defines their core insight: backing entrepreneurs who leverage technology to address significant economic and societal challenges in healthcare.
The firm supports a broad spectrum of healthcare enterprises, from early clinical development to commercial operations. Longitude Capital partners closely with its portfolio companies on strategic planning, team development, and capital raising. Their vision is to cultivate businesses driving transformative innovation, ultimately shaping a future with more effective, accessible, and efficient healthcare solutions.
Key people at Longitude Capital.
Longitude Capital was founded in 2006 by Patrick Enright (Founder and Managing Director).
Longitude Capital was founded in 2006 by Patrick Enright (Founder and Managing Director).
Longitude Capital is a venture capital firm specializing in growth-stage investments in biotechnology, medical technology, and health solutions companies. Its mission centers on improving clinical outcomes, enhancing patient quality of life, and reducing healthcare costs by backing transformative healthcare innovations. The firm employs a balanced portfolio strategy, investing primarily in clinical-stage and commercial-stage companies with clinically de-risked assets and favorable valuations, aiming for attractive returns within three to five years. Longitude Capital actively supports its portfolio companies through strategic guidance, capital raising, and operational assistance, leveraging an extensive industry network and proprietary thematic research to identify promising investment opportunities[1][2][5].
Founded in 2006, Longitude Capital has raised over $2 billion across six funds and has built a strong track record with more than 75 portfolio companies and over 35 successful exits. The firm was named after the historic Longitude Prize, symbolizing its commitment to solving significant economic and social challenges through innovative technology. Its leadership includes experienced partners with backgrounds in biology, business, and healthcare investing, who have evolved the firm’s focus to encompass a flexible investment approach across private and public companies, spin-outs, recapitalizations, and special situations[1][2][5][6].
Longitude Capital rides the ongoing trend of healthcare innovation driven by advances in biotechnology and medical technology, addressing critical needs such as improved patient outcomes and cost reduction. The timing is favorable due to increasing healthcare demands, regulatory advancements, and growing investor interest in life sciences. By investing in companies with clinically de-risked assets and near-term value-creating milestones, Longitude Capital influences the ecosystem by accelerating the development and commercialization of transformative healthcare solutions, thereby shaping the future of medical treatment and patient care[1][3][5].
Looking ahead, Longitude Capital is poised to continue expanding its platform, as evidenced by the launch of its Longitude Prime Fund focused on crossover and IPO financings of breakout portfolio companies. Trends such as personalized medicine, advanced therapeutics, and digital health will likely shape its investment focus. The firm’s influence is expected to grow as it capitalizes on its strong track record and network to back innovative healthcare companies that can deliver significant clinical and economic impact, reinforcing its role as a key player in the venture growth healthcare space[5].
Key people at Longitude Capital.
Longitude Capital has more than 26 tracked investments across 21 companies. The latest tracked deal is $200.0M Series A in AirNexis Therapeutics in January 2026.
